scholarly journals Skeletal Muscle Changes Assessed by Preoperative Computed Tomography Images Can Predict the Long‐Term Prognosis of Stage III Colorectal Cancer

2021 ◽  
Author(s):  
Keigo Yokoi ◽  
Toshimichi Tanaka ◽  
Ken Kojo ◽  
Hirohisa Miura ◽  
Takahiro Yamanashi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Computed Tomography ◽  
Skeletal Muscle ◽  
Stage Iii ◽  
Computed Tomography Images ◽  
Long Term Prognosis ◽  
Muscle Changes

Intra- and interobserver variability in skeletal muscle measurements using computed tomography images

2018 ◽  
Vol 109 ◽  
pp. 142-146 ◽  
Author(s):  
Joanna E. Perthen ◽  
Tamir Ali ◽  
David McCulloch ◽  
Maziar Navidi ◽  
Alexander W. Phillips ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Skeletal Muscle ◽  
Interobserver Variability ◽  
Computed Tomography Images

scholarly journals Is early response by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography a predictor of long-term outcome in patients with metastatic colorectal cancer?

2016 ◽  
Vol 7 (3) ◽  
pp. 365-372 ◽  
Author(s):  
Maria Nirvana da Cruz Formiga ◽  
Marcello Ferretti Fanelli ◽  
Aldo Lourenço Abadde Dettino ◽  
Ulisses Ribaldo Nicolau ◽  
Marcelo Cavicchioli ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Metastatic Colorectal Cancer ◽  
Early Response ◽  
Emission Tomography ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Positron Emission

Long-term followup of bi-shRNAfurin and GMCSF augmented autologous tumor cell immunotherapy treated colorectal cancer patients in phase I and IIa studies.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15100-e15100
Author(s):  
Minal A. Barve ◽  
Anton M. Melnyk ◽  
Luisa Manning ◽  
Gladice Wallraven ◽  
Martin Birkhofer ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cell ◽  
Phase I ◽  
Checkpoint Inhibitors ◽  
Disease Free Survival ◽  
Stage Iii ◽  
Autologous Tumor Cell ◽  
Autologous Tumor ◽  
Disease Free

e15100 Background: Vigil is an immuno-stimulatory autologous tumor cell therapy, which uses patient tumor cells transfected with a plasmid encoding genes to upregulate GM-CSF and down regulate TGFβ 1&2. It is administered monthly by intra-dermal injection. In Phase I and IIa trials patients with over 19 different tumor types were safely treated. Rapid and durable systemic immune activation was demonstrated using an IFNγ ELISPOT assay. Methods: Data are summarized for a group of 9 patients with advanced colorectal cancer followed for up to 3.5 years. Results: Six women and 3 men with Stage III or IV colorectal cancer were treated between March, 2010 and September, 2013. Six patients received Vigil as a monotherapy and 3 in combination with FOLFOX chemotherapy. Results: Demographics and treatment details are displayed below. Two patients with Stage III disease received combination therapy after complete surgical resection, and remain disease free over 3 years from surgery. The patients received 9 and 12 Vigil injections with a brisk and durable ELISPOT reactions. Conclusions: Preliminary results suggest that Vigil can be combined safely with FOLOX chemotherapy and still elicit a systemic immune response. Long term disease free survival has been observed in several patients justifying further exploration of this combination. More detailed molecular characterization and neoantigen identification of patient tumor will be undertaken in future studies. A combination with immune checkpoint inhibitors may also be explored. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document